List M A, Siston A, Haraf D, Schumm P, Kies M, Stenson K, Vokes E E
Department of Medicine, Chicago Cancer Research Center, University of Chicago, IL 60637, USA.
J Clin Oncol. 1999 Mar;17(3):1020-8. doi: 10.1200/JCO.1999.17.3.1020.
To prospectively evaluate performance and quality of life (QOL) in advanced-stage head and neck cancer (HNC) patients on a curative-intent, concomitant-chemoradiotherapy (CT/XRT) (twice-daily radiation, fluorouracil, hydroxyurea, and cisplatin) regimen aimed at improving locoregional control, survival, and QOL.
Sixty-four patients were assessed before, during, and at 3-month intervals after treatment. Standardized measures of QOL (Functional Assessment of Cancer Therapy-Head and Neck), performance (Performance Status Scale for Head and Neck Cancer Patients and Karnofsky Performance Status Rating Scale), and patient-reported symptoms (McMaster University Head and Neck Radiotherapy Questionnaire) were administered.
Acute treatment toxicities were severe, with declines in virtually all QOL and functional domains. Marked improvement was seen by 12 months; general functional and physical measures returned to baseline levels of good to excellent. Although up to a third of the patients continued to report problems with swallowing, hoarseness, and mouth pain, these difficulties were present in similar magnitudes before treatment. The following symptoms were more frequent at 12 months: dry mouth (58% v 17%), difficulties tasting (32% v 8%), and soft food diet (82% v 42%). Twelve-month diet was not related to pretreatment functioning, disease, treatment, or patient characteristics. Twelve-month QOL was best predicted by pretreatment QOL, with very little relationship to residual side effects or functional impairments. Small numbers of patients in four of the five disease sites precluded examination of outcome by site.
These data support the feasibility of intense CT/XRT as primary treatment for advanced HNC. Results confirm acute toxicity but indicate that many of the treatment-related performance and QOL declines resolve by 12 months. The persistent inability to eat a full range of foods warrants further attention and monitoring.
前瞻性评估晚期头颈癌(HNC)患者接受旨在改善局部区域控制、生存率和生活质量(QOL)的根治性同步放化疗(CT/XRT)(每日两次放疗、氟尿嘧啶、羟基脲和顺铂)方案时的治疗效果和生活质量。
对64例患者在治疗前、治疗期间及治疗后每隔3个月进行评估。采用生活质量标准化测量方法(癌症治疗功能评估-头颈)、治疗效果(头颈癌患者表现状态量表和卡诺夫斯基表现状态评定量表)以及患者报告的症状(麦克马斯特大学头颈放疗问卷)。
急性治疗毒性严重,几乎所有生活质量和功能领域均下降。到12个月时明显改善;一般功能和身体测量指标恢复到良好至优秀的基线水平。尽管多达三分之一的患者继续报告吞咽、声音嘶哑和口腔疼痛问题,但这些困难在治疗前的程度相似。以下症状在12个月时更常见:口干(58%对17%)、味觉障碍(32%对8%)和软食饮食(82%对42%)。12个月时的饮食与治疗前功能、疾病、治疗或患者特征无关。12个月时的生活质量最佳预测指标是治疗前的生活质量,与残留副作用或功能障碍关系很小。五个疾病部位中有四个部位的患者数量较少,无法按部位检查结果。
这些数据支持强化CT/XRT作为晚期HNC主要治疗方法的可行性。结果证实了急性毒性,但表明许多与治疗相关的治疗效果和生活质量下降在12个月时得到缓解。持续无法食用各种食物值得进一步关注和监测。